View
1
Download
0
Category
Preview:
Citation preview
1
21st CENTUARY BIOEQUIVALENCE
Advances & Best Practices
David W Holt Emeritus Professor of Bioanalytics
ASI Ltd St George’s – University of London
2
Disclosures
I have been a speaker for and a consultant to a variety of Pharma and Diagnostics companies including: Novartis, Astellas, Pfizer, Sanofi, Roche, Abbott, Applied Biosystems, Siemens, Thermofisher and Waters.
I am not on the pay role of any of these companies nor do I hold shares in any of them.
The content of the slides is mine.
3
Background
Director Research and service laboratory in London
GLP and GCP compliant Medicines and Healthcare products Regulatory Authority (MHRA)
Accredited by ANVISA for bioequivalence studies Drug measurements
As a guide to therapy Regulatory studies Integrity of formulations
Past President Association of Therapeutic Drug Monitoring & Clinical Toxicology
4
Overview
Why we need BE regulations Overview of regulations Complexities of regulating an expanding
market for generic formulations Some specific examples Regulation of biosimilars
5
Phenytoin Formulations
Outbreak of Anticonvulsant Intoxication in an Australian City Tyrer JH, Eadie MJ, Sutherland JM & Hooper WD British Medical Journal, 272, 271 – 273 31st October 1970
6
Phenytoin - Excipients
One patient taking 400mg/day phenytoin Outbreak of anticonvulsant intoxication in an Australian City. Tyrer et al BMJ 1970;272:27103
7
The Impact of Formulation
Heart pill twice as strong as makers expected
Wednesday August 2, 1972
8
Digoxin Bioavailability
Bioavailability affected by manufacturing process.
9
Digoxin Bioanalytics
It seems extraordinary that none of this might have come to light without the advent of methods of measuring the concentration of digoxin in plasma.
The Lancet 1972
10
Innovator Formulations
We know a lot about first into market Large regulatory dossier Pre-clinical and clinical studies Efficacy and safety studies Follow-up observations after approval
11
Generic Formulations
Following patent expiry other manufacturers can make a new formulation of the innovator drug
The regulations to bring a generic drug to market are not the same as for the innovator of the drug
Abbreviated New Drug Application (ANDA)
12
Generic Formulations
Regulations fundamentally unchanged since Hatch-Waxman Act of 1984
Established to make registration of generic products simpler No need for clinical trials of efficacy/safety Process based on bioequivalence of test
and reference products for solid dose formulations
13
Generic Formulations
Not here to dismiss generic formulations Many are of excellent quality Essential for provision of health care But not all are made to acceptable standards Can impact on safety and efficacy Need appropriate tests to show comparability
14
Generic Formulations
Much has changed since the passage of the Act Increased use of generics Of the order 75% - 80% of prescriptions
Much more complicated supply chain
15
Drug Manufacture
About 80% of API produced in China or India In USA about 40% of finished drugs imported Whilst drug production was within national
borders it was easier to monitor quality of production
Many examples of poor quality have emerged Heparin scandal of 2008
16
Recognising The Problem
“Today’s medical-product landscape blurs the line between domestic and foreign production, drawing attention to the need for global quality and safety oversight to prevent patient exposure to falsified products.”
Dr Margaret Hamburg, former US FDA Commissioner
American Journal of Tropical Medicine & Hygiene Published on line April 20, 2015
http://www.ajtmh.org/content/early/2015/04/16/ajtmh.14-0393
17
Bioequivalence
Why do we need precise regulations? Increased use of generic formulations Increase in generic-generic substitution To engender confidence in therapeutic
efficacy and safety of multiple formulations of the same drug that are on sale
18
FDA Guidance
http://www.fda.gov/ohrms/dockets/ac/03/briefing/3995B1_07_GFI-BioAvail-BioEquiv.pdf
19
Proposed Guidance
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM377465.pdf
20
EMA Guidance
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf
21
International Regulations
International Generic Drug Regulators Pilot Australia, Brazil, Canada, China, Taipei, EMA, Japan, Mexico, Singapore, South Korea, Switzerland, FDA, WHO
22
International Regulations
Demonstrate bioequivalence to the reference product
Mostly by randomised, single-dose, two-way crossover studies in healthy normal subjects
At least 12 subjects, often 18-24 Age range and body weight restrictions Mostly both male and female subjects
Davit B et al 2013
23
Bioequivalence
For most products, the focus of bioequivalence (BE) studies is on the release of the drug substance from the drug product into the systemic circulation. During such BE studies, an applicant compares the systemic exposure profile of a test drug product to that of the Reference Listed Drug (RLD).
FDA Guidance
24
Bioequivalence Blood Concentration Data
Blood concentration / time profile
Peak concentration – Cmax
Time to reach Cmax – tmax
Area under time/conc. curve – AUC
25
Comparing Formulations
0
100
200
300
400
500
600
700
800
900
0 4 8 12 16 20 24
Time
Con
cent
ratio
n
AUC Cmax
tmax
26
Bioequivalence
“A drug shall be considered to be bioequivalent to a listed drug if the rate and extent of absorption of the drug do not show a significant difference from the rate and extent of the listed drug” FDA Guidance
27
Bioequivalence
Study Types As noted in 21 CFR 320.24, in vivo
and/or in vitro methods can be used to establish BE. In general descending order of preference, these include pharmacokinetic, pharmacodynamic, clinical, and in vitro studies.
FDA Guidance
28
Bioavailability measures the rate and extent of drug appearance in the systemic circulation
Bioequivalence demonstrates that
other drug formulations have comparable bioavailability to an already approved drug product
Bioequivalence
29
Bioequivalence
The 90% confidence interval of the mean ratios for Cmax and AUC should lie within an acceptance interval of 80 to 125%
30
The Fundamental Bioequivalence Assumption
If two formulations are shown to be bioequivalent, it is assumed that they will reach the same therapeutic effect, are therapeutically equivalent and, hence, can be used interchangeably.
31
Generic Substitution Psychiatry
• Bupropion - Early 2007 Switch from 300mg Wellbutrin XL to Budeprion XL FDA received 85 post-marketing reports
78 specifically about loss of efficacy Also
• Increased incidence of adverse events • New or different adverse events
Bioequivalence at 150mg (90% CI) Cmax Fasted 80.3 – 98.2% Fed 103.2 - 118.0
www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm153270.htm, accessed January 12, 2012
32
FDA’s Position January 2012
Small differences in the pharmacokinetic profiles
Not outside the established boundaries for equivalence
The FDA considers bupropion XL 300mg (Teva) bioequivalent and therapeutically equivalent to (interchangeable with) Wellbutrin XL 300mg
www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm153270.htm, accessed January 12, 2012
33
FDA’s Position January 2012
www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm153270.htm, accessed January 12, 2012
34
FDA Reviews Its Position
http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm322161.htm, 2012/10/08
FDA Update: Budeprion XL 300mg Not Therapeutically Equivalent to Wellbutrin XL 300mg
35
Generic Budeprion Withdrawn
NEnglJMed 2012;367:2463-5
36
Generic Substitution
Br J Clin Pharmacol 2011;72:727-30
37
Generic Substitution
“There are few prospective studies assessing potential additional risks associated with substitution and there are no established protocols by which switching is monitored or assessed.
This may make it difficult to know whether the money saved on the initial drug will still be saved as treatment outcomes on the substituted drug become apparent.”
Br J Clin Pharmacol 2011;72:727-30
38
The FDA’s Position
http://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/UnderstandingGenericDrugs/ucm305896.htm, accessed August 19th, 2013
FDA is aware that there are reports that some people may experience undesired effect when switching from a brand name drug to a generic formulation …
39
Comparing Formulations
http://www.jwatch.org/fw108810/2014/05/09/fda-planning-study-generic-metoprolol-over-safety
40
Comparing Formulations
http://www.peoplespharmacy.com/2014/05/15/metoprolol-mess-toprol-xl-reveals-serious-flaws-with-fdas-generic-process/
Wockhardt’s generic metoprolol succinate did not pass dissolution tests.
41
Switching Formulations
The Annals of Pharmacotherapy n 2012 December, Volume 46, 1609-16
42
Warfarin Formulations
“The use of both generic and branded formulations of warfarin interchangeably, or the use of generics from more than one manufacturer, was associated with increased use of all-cause health care resources and total costs in patients with AF.”
The Annals of Pharmacotherapy n 2012 December, Volume 46
43
Warfarin Formulations
The Annals of Pharmacotherapy 2011;45:701-12
Thrombotic adverse events
44
Switching Formulations
45
Phenytoin Formulations
Generic to generic switching of phenytoin Formulations approved as interchangeable 80 patients Primary outcome - increased seizure frequency Event rate increased significantly Need for increased monitoring emphasised
Shin J-W et al Int J Clin Pharmacol Ther 2014;52:1017-22
46
Tacrolimus Formulations
Prescribers should prescribe oral tacrolimus products by brand name only. When prescriptions have previously been written using the generic name, the brand on which the patient is stabilised should be established to ensure that the patient is supplied with the same product. If a prescriber intends to switch between any tacrolimus brands, careful medical supervision and therapeutic monitoring are required. CORRESPONDENCE TO: SECRETARY OF COMMISSION, L.R. WHITBREAD, FLOOR 4-T 151 BUCKINGHAM PALACE ROAD, LONDON SW1W 9SZ TEL NO: 020 3080 6451/2 OR 020 3080 6477 ♦ EMAIL: leslie.whitbread@mhra.gsi.gov.uk
47
Switching Formulations
Generic tacrolimus was not bioequivalent in elderly renal transplant patients. The significantly higher systemic exposure of tacrolimus, despite similar trough concentrations, may in the long run increase the risk of adverse effects
Transplantation 2015; 99:528-32
48
Therapeutically Equivalent?
Verapamil Young volunteers
Generic bioequivalent Generic PK more variable
Elderly patients Not bioequivalent
Generic Cmax +77% AUC +43%
Not therapeutically equivalent Generic prolonged PR
interval 60
80
100
120
140
160
180
200
220
240
Cmax AUC
Rat
io%
Tes
t to
Ref
eren
ce
177%
143%
Carter BL et al, Pharmacotherapy 13(4), 359, 1993
49
Clinical Observations
Clinical indications requiring multiple observations tend to highlight any differences due to the formulation Anticoagulants Anticonvulsants Immunosuppression
Less easy to assess effects on chronic therapy when fewer clinical observations made Hypertension Lipid lowering
50
Generic Substitution
51
Generic Substitution
20 pharmacies in Pennsylvania sampled for availability of atorvastatin
Sample × 4 for 4 months from 10/14 6 pharmacies – different generic each month 2 pharmacies – same product each month
Bate R et al 2015
52
Pharmacovigilance of Generics
Often anecdotal Small patient numbers History of prescription may be poor Brands used Batch numbers Manufacturers Unknown to prescribing physician
Of particular importance for NTI drugs
53
EMA Guideline
54
EMA Guideline
Narrow Therapeutic Index Drugs “It is not possible to define a set of criteria
to categorise drugs as narrow therapeutic index (NTIDs) and it must be decided case by case if an active substance is an NTID based on clinical considerations”
Verbeeck RK & Musuamba FT 2012
55
EMA Guideline
Narrow Therapeutic Index Drugs Ciclosporin and tacroimus classed as NTID
Ciclosporin 90.00 – 111.11% for AUC and Cmax
Tacrolimus 90.00 – 111.11% for AUC only No consensus on switchability within EU States
Verbeeck RK & Musuamba FT 2012
56
Product-specific Guidance
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/04/WC500185420.pdf
57
Sirolimus
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/11/WC500154323.pdf
58
NTI Drugs
Clin Pharmacol Ther 2015;97:286-91
59
NTI Drugs
Narrow therapeutic ratio 1. There is less than a two-fold difference in
median lethal dose (LD50) and median effective dose (ED50) values or there is less than a two-fold difference in the minimum toxic concentrations and mimimum effective concentrations in blood, and
2. Safe and effective use of the drug products require careful titration and patient monitoring.
Clin Pharmacol Ther 2015;97:286-91
21 CFR 320.33
60
NTI Drugs
FDA now uses NTI Those drugs where small differences in dose or
blood concentration may lead to serious therapeutic failure and/or adverse drug reactions that are life-threatening or result in persistent or significant disability or incapacity. The FDA believes that NTI drug products require tighter BE limits and product quality standards.
Clin Pharmacol Ther 2015;97:286-91
Follows FDA Advisory Committee meetings 2010 and 2011
Examples: Warfarin, lithium, digoxin, phenytoin, theophylline, tacrolimus
61
NTI Drugs
Proposed FDA approach Four-way cross-over study Allows comparison of variability in
addition to means Termed reference scaled bioequivalence Described in draft guidance for warfarin
Clin Pharmacol Ther 2015;97:286-91
62
Comparing Formulations
Bioequivalence testing Quality of production Were the test batches used in the BE study the
same quality as the final marketed formulation? Continuing onsite inspections
Were the bioanalytical methods used in the study appropriate and to international standards?
63
A Medicine
Is the sum of many parts Active pharmaceutical ingredient (API) Excipients Packaging Indications for its use Dosing instructions
We expect consistency Attained by the quality of manufacture
64
Quality Issues
http://features.blogs.fortune.cnn.com/2013/05/15/ranbaxy-fraud-lipitor - accessed May 19, 2013
65
Quality Issues
On May 13, Ranbaxy pleaded guilty to seven federal criminal counts of selling adulterated drugs with intent to defraud, failing to report that its drugs didn't meet specifications, and making intentionally false statements to the government. Ranbaxy agreed to pay $500 million in fines, forfeitures, and penalties -- the most ever levied against a generic-drug company.
http://features.blogs.fortune.cnn.com/2013/05/15/ranbaxy-fraud-lipitor - accessed May 19, 2013
66
Flawed BE Studies
http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/GVK_Biosciences_31/WC500180899.pdf
67
Regulatory Inspections
http://www.outsourcing-pharma.com/Contract-Manufacturing/Exporting-to-Brazil-ANVISA-is-tough-and-hands-on-says-Kemwell/ June 12, 2015
68
Generic Ophthalmics
Can J Ophthalmol 2012;47:55-61
American and Canadian Timoptic XE eye drops vary significantly from the generics in drop volume, viscosity, surface tension and bottle tip.
69
Generic Ophthalmics
Br J Ophthalmol 2013;97:253–7
70
The Packaging
11 people arrested in Zhejiang, China, in connection with the manufacture of capsule casings that contained chromium above acceptable limits
No licence to manufacture for drug use Industrial grade gelatin used
RX-360 Flash Report, November 2014 www.Rx-360.org
71
Imatinib
Treatment of chronic myeloid leukaemia Controversies surrounding form of API
and quality of manufacture Crystallises in two polymorphic forms alpha and beta forms
Regulatory data relates to the beta form
72
Imatinib
http://www.bccancer.bc.ca/chemotherapy-protocols-site/Documents
73
Imatinib Polymorphs
J Pharm Sci 2012;101:541-51
74
Imatinib
75
Product-specific Guidance
76
Imatinib
http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002585/WC500134083.pdf
77
Imatinib
MHRA licenced a generic form – Nibix – under the decentralised procedure
Refused a FOI request for information on the polymorphic form of the API
Transparency A key aim of the new legislation includes strengthening
medicines safety transparency and communication to increase understanding and trust of healthcare professionals and patients in the safety of medicines, and improving penetration of key warnings.
https://www.gov.uk/drug-safety-update/public-consultation-on-new-pharmacovigilance-legislation
78
Bioanalytics
79
Bioanalytics
80
Bioanalytics
81
Quality Issues
One of the recurring allegations made in the latest letter is that tests purporting to cover stability analysis over a nine month period were actually carried out on the “ same day or within a few days of each other.”
http://www.in-pharmatechnologist.com/Processing/Ranbaxy-made-untrue-statement-in-filings-says-FDA
82
Bioanalytics
ANVISA For bioequivalence studies laboratory
must be accredited by ANVISA
83
Biologicals
84
Biologicals
Complex proteins derived from unique cell lines and purification processes
May trigger immune reactions Conventional BE for follow-on products
inadequate Process includes pre-clinical and clinical
studies
85
Bioanalytical Comparisons
EMA Guidance “extensive state-of-the art characterization
studies need to be applied to the biosimilar and reference medicinal product (originator) in parallel, to demonstrate with a high level of assurance that the quality of the biosimilar is comparable to the reference medicinal product”
86
Biological in Brazil
http://cphi-online.com/News/Show/19661/ANVISA_Approves_First_Infliximab_Biosimilar_in_Brazil?cid=digital_conews_week22#.VXQQ3-9FB9A
87
ABPI - Biosimilars
Published 050213 http://www.abpi.org.uk/our-work/library/industry/Pages/biosimilars-position-paper.aspx
88
ABPI - Biosimilars
Prescribe by brand name not by INN Facilitate identification and traceability for PV
No substitution without consent of physician Automatic substitution of one biological medicine
for another makes post-marketing surveillance more difficult
Patients must be informed and consulted Make a fully-informed decision on any switches
Published 050213 http://www.abpi.org.uk/our-work/library/industry/Pages/biosimilars-position-paper.aspx
89
Conclusions
Differing levels of resources and commitment to regulatory procedures Production Testing of comparability
Fundamental to acceptance of generics Confidence in the Regulator Adherence to accepted quality standards Consistency of production Ongoing clinical assessment
Move away from One approach fits all
90
Contact Details
David W Holt BSc, PhD, DSc (Med), CSci, EuSpLM, FESC, FBPhS, FRCPath
Emeritus Professor of Bioanalytics
Analytical Services International Ltd @
St George’s - University of London London SW17 0RE
UK
david.holt@bioanalytics.co.uk
91
Slides
URL http://www.bioanalytics.co.uk/BE_Brasilia_0615.html
Recommended